Background: Gastric cancer (GC) is one of the leading causes of cancer death in China, while the nature of genetic factors related to GC has not been well-studied. Objectives: To assess the inherited genetic factors regarding pathogenic germline mutations in Chinese GC population. Methods: Genomic profiling of DNA was performed through next-generation sequencing with 381 cancer-related genes on tissue from patients with GC between January 1, 2017, and May 7, 2019. Results: 470 GC patients were included for analysis. A total of 28 (6.0%) patients were identified to harbor 25 different pathogenic or very likely pathogenic germline mutations in 15 genes. The variants fell most frequently in BRCA2 (n = 6, 1.28%), CHEK2 (n = 5, 1.06%), MUTYH (n = 3, 0.64%), CDH1 (n = 2, 0.43%), and ATM (n = 2, 0.43%). Of all the germline-mutated genes, 66.7% (n = 10) lay in the DNA damage repair pathways. Seven patients were identified to have a high TMB status, among whom two were also identified as MSI-H. Overall, 20 out of the 28 patients (71.4%) carried clinically actionable mutations. Conclusions: Our study has depicted the spectrum of pathogenic germline mutations in Chinese GC patients, which may provide valuable clues for the assessment of the genetic susceptibility and clinical management in GC.

1.
Chen
W
,
Zheng
R
,
Baade
P
,
Zhang
S
,
Zeng
H
,
Bray
F
, et al
Cancer statistics in China, 2015
.
CA Cancer J Clin
.
2016
;
66
(
2
):
115
32
. .
2.
La Vecchia
C
,
Negri
E
,
Franceschi
S
,
Gentile
A
.
Family history and the risk of stomach and colorectal cancer
.
Cancer
.
1992
;
70
(
1
):
50
5
. .
3.
Su
D
,
Zhang
D
,
Chen
K
,
Lu
J
,
Wu
J
,
Cao
X
, et al
High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods
.
J Exp Clin Cancer Res
.
2017
;
36
(
1
):
121
. .
4.
Richards
S
,
Aziz
N
,
Bale
S
,
Bick
D
,
Das
S
,
Gastier-Foster
J
, et al
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
.
Genet Med
.
2015
;
17
(
5
):
405
24
. .
5.
Boku
N
.
Her2-positive gastric cancer
.
Gastric Cancer
.
2014
;
17
:
1
12
. .
6.
Guilford
P
,
Hopkins
J
,
Harraway
J
,
McLeod
M
,
McLeod
N
,
Harawira
P
, et al
E-cadherin germline mutations in familial gastric cancer
.
Nature
.
1998
;
392
(
6674
):
402
5
. .
7.
Fitzgerald
R
,
Hardwick
R
,
Huntsman
D
,
Carneiro
F
,
Guilford
P
,
Blair
V
, et al
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research
.
J Med Genet
.
2010
;
47
(
7
):
436
44
. .
8.
Gaston
D
,
Hansford
S
,
Oliveira
C
,
Nightingale
M
,
Pinheiro
H
,
Macgillivray
C
, et al
Germline mutations in map3k6 are associated with familial gastric cancer
.
PLoS Genet
.
2014
;
10
(
10
):
e1004669
.
9.
Majewski
IJ
,
Kluijt
I
,
Cats
A
,
Scerri
TS
,
de Jong
D
,
Kluin
RJ
, et al
An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer
.
J Pathol
.
2013
;
229
(
4
):
621
9
.
10.
Weren
R
,
van der Post
R
,
Vogelaar
I
,
van Krieken
J
,
Spruijt
L
,
Lubinski
J
, et al
Role of germline aberrations affecting ctnna1, map3k6 and myd88 in gastric cancer susceptibility
.
J Med Genet
.
2018
;
55
:
669
74
. .
11.
Sahasrabudhe
R
,
Lott
P
,
Bohorquez
M
,
Toal
T
,
Estrada
A
,
Suarez
J
, et al
Germline mutations in palb2, brca1, and rad51c, which regulate DNA recombination repair, in patients with gastric cancer
.
Gastroenterology
.
2017
;
152
(
5
):
983
86.e6
. .
12.
Huang
K
,
Mashl
R
,
Wu
Y
,
Ritter
D
,
Wang
J
,
Oh
C
, et al
Pathogenic germline variants in 10,389 adult cancers
.
Cell
.
2018
;
173
:
355
70.e314
. .
13.
Gourley
C
,
Balmana
J
,
Ledermann
J
,
Serra
V
,
Dent
R
,
Loibl
S
, et al
Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy
.
J Clin Oncol
.
2019;37:2257
. .
14.
Mateo
J
,
Porta
N
,
Bianchini
D
,
McGovern
U
,
Elliott
T
,
Jones
R
, et al
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
.
Lancet Oncol
.
2020
;
21
(
1
):
162
74
. .
15.
Goodall
J
,
Mateo
J
,
Yuan
W
,
Mossop
H
,
Porta
N
,
Miranda
S
, et al
Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition
.
Cancer Discov
.
2017
;
7
(
9
):
1006
17
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.